BridgeBio Pharma (Nasdaq: BBIO) announced it will present primary results from its Phase 3 PROPEL 3 trial of oral infigratinib ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE